Who Paid My Doc
Jennifer Hill
Urogynecology and Reconstructive Pelvic Surgery Riverhead, NY Medical Doctor
NPI 1932390150 CMS profile 224237
74 Commerce Ave Ste 1, Riverhead, NY 11901
General payments
$12,725
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jennifer Hill of Riverhead, NY is reported in the CMS Open Payments database as having received $12,725 across 118 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 64th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $5,286 | 6 | |
| 2024 | General | $3,664 | 29 | |
| 2023 | General | $1,479 | 29 | |
| 2022 | General | $176 | 6 | |
| 2021 | General | $1,244 | 18 | |
| 2020 | General | $271 | 7 | |
| 2019 | General | $605 | 23 |
Beside peers
- Jennifer Hill
- Urogynecology and Reconstructive Pelvic Surgery median
- Middle half of Urogynecology and Reconstructive Pelvic Surgery
- National median
In program year 2025, general payments to Jennifer Hill were reported at $5,286. Among 149 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $779 and the middle half received between $301 and $2,705.
Show as a table
| Year | Jennifer Hill | Urogynecology and Reconstructive Pelvic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $605 | $799 | $319–$2,013 | $163 |
| 2020 | $271 | $384 | $158–$1,360 | $114 |
| 2021 | $1,244 | $641 | $247–$2,515 | $132 |
| 2022 | $176 | $843 | $347–$2,794 | $149 |
| 2023 | $1,479 | $819 | $308–$2,302 | $160 |
| 2024 | $3,664 | $882 | $306–$2,459 | $164 |
| 2025 | $5,286 | $779 | $301–$2,705 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
823
Drug cost
$214,618
Branded share of claims
59.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Gemtesa Vibegron | Brand | 112 | $107,007 | |
| Myrbetriq Mirabegron | Brand | 55 | $63,725 | |
| Estradiol | Generic | 143 | $11,574 | |
| Estring Estradiol | Brand | 15 | $7,925 | |
| Mirabegron Er Mirabegron | Brand | 11 | $6,798 | |
| Solifenacin Succinate | Generic | 34 | $3,888 | |
| Desmopressin Acetate | Generic | 23 | $3,346 | |
| Cefuroxime Cefuroxime Axetil | Brand | 89 | $2,012 | |
| Estradiol (Twice Weekly) Estradiol | Brand | 12 | $1,711 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 50 | $1,414 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 48 billing codesPaid by Medicare
$42,015
Medicare patients
161
Services billed
433
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 64% | |
| Depression | 37% | |
| Diabetes | 32% | |
| Osteoporosis | 27% | |
| Chronic kidney disease | 24% | |
| Atrial fibrillation | 22% | |
| Ischemic heart disease | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
118 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Urogynecology and Reconstructive Pelvic Surgery in New York
Jason Kim
Urogynecology and Reconstructive Pelvic Surgery · Stony Brook, NY
Robert Moldwin
Urogynecology and Reconstructive Pelvic Surgery · New Hyde Park, NY
Nitya Abraham
Urogynecology and Reconstructive Pelvic Surgery · Bronx, NY
Abeer Eddib
Urogynecology and Reconstructive Pelvic Surgery · Cheektowaga, NY
Wai Lee
Urogynecology and Reconstructive Pelvic Surgery · New Hyde Park, NY
Doreen Chung
Urogynecology and Reconstructive Pelvic Surgery · New Hyde Park, NY
Related records
Urogynecology and Reconstructive Pelvic Surgery in New York
Practitioners in the same specialty and state, ranked by reported value.
All Urogynecology and Reconstructive Pelvic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.